Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
`[18F]AlF-NOTA-QHY-04` is an investigational, fluorine-18 labeled, NOTA-conjugated cyclic polypeptide radiotracer designed for positron emission tomography (PET) imaging. It specifically targets C-X-C chemokine receptor type 4 (CXCR4), a G-protein coupled receptor that is highly overexpressed in various hematologic malignancies and solid tumors, as well as in inflammatory conditions. Developed by academic research groups in China, including the Shandong Cancer Hospital and Institute, the tracer utilizes an aluminum-fluoride ([18F]AlF) labeling strategy with the NOTA chelator, resulting in a highly hydrophilic complex with favorable pharmacokinetics, rapid renal clearance, and low background brain uptake. In clinical studies, [18F]AlF-NOTA-QHY-04 PET/CT has demonstrated high diagnostic accuracy and tumor-to-background contrast in detecting primary central nervous system lymphoma (PCNSL), small cell lung cancer (SCLC), and gliomas. It has also shown utility in predicting treatment response and progression-free survival in limited-stage SCLC patients undergoing chemoradiotherapy, as well as in the early detection of radiation-induced lung, brain, and esophageal injuries.
| Indication | Highest phase | Status |
|---|---|---|
| acquired brain injury (ABI) | In development | Active |
| acute lung injury syndromes | In development | Active |
| colorectal cancer (CRC) and precursor lesions | In development | Active |
| diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) | In development | Active |
| hepatocellular carcinoma (HCC) | In development | Active |
| limited-stage small-cell lung cancer (LS-SCLC) | In development | Active |
| non-small-cell lung cancer (NSCLC) | In development | Active |
| pancreatic cancer and precursor lesions | In development | Active |
| primary central nervous system lymphoma (PCNSL) | In development | Active |
| radiation-induced cognitive impairment / radiation-induced cognitive dysfunction (RICI / RICD) | In development | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: acquired brain injury (ABI)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]AlF-NOTA-QHY-04.
Work on [18F]AlF-NOTA-QHY-04? Claim this page to correct or add information. Claim this page